DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Afelimomab

Afelimomab

  • Therapeutic and Prophylactic Use of Oral, Low-Dose Ifns in Species of Veterinary Interest: Back to the Future

    Therapeutic and Prophylactic Use of Oral, Low-Dose Ifns in Species of Veterinary Interest: Back to the Future

  • Afelimomab (Rinn) Ic Medicines Under the Following Names: Adonis V

    Afelimomab (Rinn) Ic Medicines Under the Following Names: Adonis V

  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub

  • (12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub

  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

  • Antitnf-Α Strategy: Present Status of This Therapeutic Paradigm J

    Antitnf-Α Strategy: Present Status of This Therapeutic Paradigm J

  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

  • Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of Ro5459072 in Patients with Primary Sjögren’S Syndrome

    Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of Ro5459072 in Patients with Primary Sjögren’S Syndrome

  • INN Working Document 05.179 Update 2011

    INN Working Document 05.179 Update 2011

  • IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*

    IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*

  • International Nonproprietary Names (Inn) for Biological and Biotechnological Substances

    International Nonproprietary Names (Inn) for Biological and Biotechnological Substances

  • (INN) for Biological and Biotechnological Substances

    (INN) for Biological and Biotechnological Substances

  • A New Venue of TNF Targeting

    A New Venue of TNF Targeting

  • WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT

    WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT

  • (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep

    (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep

  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

  • Introduction to Diagnostic and Therapeutic Monoclonal Antibodies

    Introduction to Diagnostic and Therapeutic Monoclonal Antibodies

  • WO 2014/093640 Al 19 June 2014 (19.06.2014) P O P C T

    WO 2014/093640 Al 19 June 2014 (19.06.2014) P O P C T

Top View
  • Atc Index 2009
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0055072 A1 Gant Et Al
  • Wo 2010/095940 A2
  • Antibody-Drug Analogues
  • No 480/97 Amending Annex I to Council Regulation
  • ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
  • Customs Tariff - Schedule Xxi - 1
  • This PDF Is Available for Free Download from a Site Hosted by Medknow Publications
  • Certolizumab Pegol - Drugbank
  • 210311 Wild Guided Report.Indd
  • IJCCM July 07.Indd
  • Harmonized Tariff Schedule of the United States (2006) (Rev
  • Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
  • Monneret AER SEPSIS 2017 V2
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
  • JMSCR Vol||05||Issue||02||Page 18109-18118||February 2017
  • Organización Mundial Del Comercio
  • Immunomodulatory Treatment for the Intractable Paediatric Epilepsies Luis E


© 2024 Docslib.org    Feedback